Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more
Market Cap & Net Worth: Shield Therapeutics plc (SHIEF)
Shield Therapeutics plc (OTCQB:SHIEF) has a market capitalization of $36.31 Million ($36.31 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #27139 globally and #9108 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shield Therapeutics plc's stock price $0.03 by its total outstanding shares 1067997016 (1.07 Billion).
Shield Therapeutics plc Market Cap History: 2019 to 2025
Shield Therapeutics plc's market capitalization history from 2019 to 2025. Data shows change from $2.62 Billion to $36.31 Million (-46.67% CAGR).
Shield Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shield Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.21x
Shield Therapeutics plc's market cap is 1.21 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.62 Billion | $719.00K | -$8.80 Million | 3637.43x | N/A |
| 2020 | $1.42 Billion | $10.39 Million | -$2.63 Million | 137.17x | N/A |
| 2021 | $598.08 Million | $1.52 Million | -$19.34 Million | 393.73x | N/A |
| 2022 | $85.23 Million | $4.47 Million | -$40.44 Million | 19.08x | N/A |
| 2023 | $89.18 Million | $13.09 Million | -$33.29 Million | 6.82x | N/A |
| 2024 | $39.09 Million | $32.18 Million | -$27.18 Million | 1.21x | N/A |
Competitor Companies of SHIEF by Market Capitalization
Companies near Shield Therapeutics plc in the global market cap rankings as of March 18, 2026.
Key companies related to Shield Therapeutics plc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Shield Therapeutics plc Historical Marketcap From 2019 to 2025
Between 2019 and today, Shield Therapeutics plc's market cap moved from $2.62 Billion to $ 36.31 Million, with a yearly change of -46.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $36.31 Million | -7.10% |
| 2024 | $39.09 Million | -56.17% |
| 2023 | $89.18 Million | +4.64% |
| 2022 | $85.23 Million | -85.75% |
| 2021 | $598.08 Million | -58.02% |
| 2020 | $1.42 Billion | -45.52% |
| 2019 | $2.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shield Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.31 Million USD |
| MoneyControl | $36.31 Million USD |
| MarketWatch | $36.31 Million USD |
| marketcap.company | $36.31 Million USD |
| Reuters | $36.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.